ABT Stock: Goldman Sachs Cuts Price Target to $121 as Abbott Nears 52-Week Low

April 10, 2026

By TrendSpider Editor

ABT Stock: Goldman Sachs Cuts Price Target to $121 as Abbott Nears 52-Week Low

Goldman Sachs analyst David Roman reaffirmed a "buy" rating on Abbott Laboratories today but slashed the price target from $140 to $121, a reduction of $19, as shares trade near their lowest levels in the past year. Abbott is currently priced at $100.57, down 2.09% on the session, and sits just above its 52-week low of $100.875 within a range that extends as high as $139.05. The confirmation of a bullish rating provides a degree of institutional support, but the steep target cut raises questions about the near-term fundamental picture for the medical device and diagnostics giant.

Key Drivers of the ABT Stock Move

Main Catalyst: Goldman Sachs analyst David Roman confirmed a "buy" rating on ABT while cutting the price target by $19, from $140 down to $121. The action reflects a meaningful reduction in the firm's expected upside even as the analyst maintains a constructive long-term view on the name.
Bull Case: Goldman's maintained "buy" rating signals that the firm views the current price of $100.57 as an attractive entry point relative to the revised $121 price target, implying potential upside of roughly 20% from current levels. A confirmed buy from a major Wall Street firm near 52-week lows can attract value-oriented and institutional buyers.
Bear Case: The $19 reduction in the price target is a significant downward revision and suggests Goldman Sachs has materially lowered its expectations for Abbott's business performance or valuation multiple. Trading at $100.57, ABT is within striking distance of its 52-week low of $100.875, and a break below that level could accelerate selling pressure and signal further deterioration in market sentiment.

Abbott is navigating a challenging environment for large-cap medical device and diagnostics companies, with the stock having shed considerable ground from its 52-week high of $139.05. The Goldman price target cut, while paired with a maintained buy, suggests the analyst community is recalibrating expectations, possibly around slower-than-expected growth in key segments such as medical devices or diagnostics. With ABT now hovering just below its 52-week low, the stock is at a technically critical inflection point. A failure to hold the $100.875 support level heading into the next trading sessions could open the door to further downside, while any positive fundamental catalysts or broader market stabilization could allow the stock to build a base here and work toward the $121 consensus target.

ABT Analyst Ratings and Price Targets

Goldman Sachs analyst David Roman confirmed a "buy" rating on Abbott Laboratories today, April 10, 2026, while lowering the price target from $140 to $121. The average price target following this action stands at $121. The confirmation of the buy rating is notable given the magnitude of the target cut, suggesting the firm remains constructive on the long-term thesis but acknowledges that the path to recovery may be longer or more uncertain than previously anticipated.

ABT Seasonality

The second quarter has historically been a period of transition for Abbott as the company prepares for its quarterly earnings release, which often serves as a catalyst for directional moves in the stock. Analyst target adjustments ahead of earnings season, as seen today, frequently set the tone for how institutional investors position into the print.

ABT Relative Performance

Abbott's 2.09% decline today places it under meaningful pressure relative to the broader healthcare sector. With the stock trading at $100.57, ABT is significantly below the midpoint of its 52-week range of $100.875 to $139.05, underperforming peers that have shown more resilience in recent sessions. The proximity to the 52-week low distinguishes Abbott as one of the weaker performers within the large-cap medical device space over the trailing year.